MedPath

The Effect of Probiotic Supplementation on Cognitive and Emotional Functions in Healthy Elderly Subjects

Not Applicable
Completed
Conditions
Healthy
Interventions
Dietary Supplement: Placebo
Dietary Supplement: Lactobacillus rhamnosus and Bifidobacterium lactis
Registration Number
NCT04828421
Lead Sponsor
Universidad de Almeria
Brief Summary

This study evaluates the cognitive and emotional effects of probiotics in healthy elderly patients.

Detailed Description

Gut microbiota (GM) has focused as an important target for emotional and cognitive diseases, moreover in a population that show an altered GM such as elderly population as age-related changes. Several studies have shown that ageing alter GM, both in diversity and integrity.

Probiotics have demonstrated that correct or prevent age-related dysbiosis, in order to reduce or prevent intestinal permeability and associated inflammation, inhibit the generation of harmful and/or toxic metabolites, as well as promote the production of beneficial bacterial components.

The aim of this study is to assess the effectiveness of a multiprobiotic formulation as a therapeutic strategy to attenuate the emotional and cognitive decline associated with ageing in healthy adults over 55 years of age. The hypothesis is that administration of a multi-species probiotic for 10 weeks will slow and/or ameliorate the decline in emotional and cognitive function inherent to senescence.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • be aged 55 years or over,
  • voluntarily agree to participate in the study in accordance with the Helsinki declaration,
  • not be participating in another study that could interfere with the results.
Read More
Exclusion Criteria
  • suffer from any serious mental illness other than depression and anxiety,
  • score below 10 on the Mini-Mental State Examination (MMSE) (severe cognitive impairment)
  • be using medications that affect cognition,
  • taking anti-inflammatory drugs, antipsychotics, antibiotics and/or anxiolytics,
  • have a serious illness (e.g. cancer, Parkinson's or Alzheimer's).
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Placebo groupPlaceboParticipants will receive a harmless substance (potato starch) during 10 weeks.
Probiotic groupLactobacillus rhamnosus and Bifidobacterium lactisParticipants will be treated with a daily capsule of a multi-species probiotic (3.3 billion Lactobacillus rhamnosus and Bifidobacterium lactis) during 10 weeks.
Primary Outcome Measures
NameTimeMethod
Change from Baseline Depression at 10 weeksBefore and after treatment (10 weeks)

The Beck Depression Inventory. Score range: 0-63.

Change from Baseline General Cognitive Status at 10 weeksBefore and after treatment (10 weeks)

Mini-Mental State Examination. Score range: 0-35

Change from Baseline Motor impulsivity or inhibitory response at 10 weeksBefore and after treatment (10 weeks)

Go/No-Go task

Change from Baseline Planning Ability at 10 weeksBefore and after treatment (10 weeks)

Tower of London test

Change from Baseline Problem-solving ability at 10 weeksBefore and after treatment (10 weeks)

Wisconsin Card Sorting test

Change from Baseline Visual Attention at 10 weeksBefore and after treatment (10 weeks)

Trail Making Test

Change from Baseline Selective attention, cognitive flexibility and response inhibition at 10 weeksBefore and after treatment (10 weeks)

Stroop task

Change from Baseline Anxiety at 10 weeksBefore and after treatment (10 weeks)

The State-Trait Anxiety Inventory. Score range: 20-80

Change from Baseline Working Memory at 10 weeksBefore and after treatment (10 weeks)

Digits task, Corsi task

Change from Baseline Choice impulsivity or impulsive decision-making at 10 weeksBefore and after treatment (10 weeks)

Iowa Gambling Task

Secondary Outcome Measures
NameTimeMethod
Change from Baseline Body Composition at 10 weeksBefore and after treatment (10 weeks)

Fat mass. Body fat mass. Fat-free mass. Total body water.

Change from Baseline Gastrointestinal Symptom at 10 weeksBefore and after treatment (10 weeks)

Gastrointestinal Symptom Rating Scale

Change from Baseline Food Habits at 10 weeksBefore and after treatment (10 weeks)

"24-hour recall" questionnaire

Change from Baseline Sleep Quality at 10 weeksBefore and after treatment (10 weeks)

The Pittsburgh Sleep Quality Index Questionnaire. Score range: 0-21

Change from Baseline Stool Consistency at 10 weeksBefore and after treatment (10 weeks)

The Bristol Scale

Change from Baseline Perceived Stress at 10 weeksBefore and after treatment (10 weeks)

Perceived Stress Questionnaire. Score range: 0-1

Change from Baseline Alcohol Use at 10 weeksBefore and after treatment (10 weeks)

The Alcohol Use Disorders Identification Test. Score range: 0-40

Change from Baseline Physical Activity at 10 weeksBefore and after treatment (10 weeks)

International Physical Activity Questionnaire

Trial Locations

Locations (2)

Pablo Roman

🇪🇸

Almeria, Spain

Universidad de Almeria

🇪🇸

La Cañada de San Urbano, Almeria, Spain

© Copyright 2025. All Rights Reserved by MedPath